Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 13/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796402 | 1.00 | PRKDC (1.00) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL6796396 | 1.00 | PRKDC (1.00) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL6396107 | 0.81 | PRKDC (0.68) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL6396110 | 0.81 | PRKDC (0.68) | PRKDCAURKAAURKBSRCFGFR1 | |
| SCHEMBL3802701 | 0.76 | AURKA (0.68) | PRKDCAURKAAURKBFGFR1KDR | |
| SCHEMBL3802699 | 0.76 | AURKA (0.68) | PRKDCAURKAAURKBFGFR1KDR | |
| SCHEMBL3796467 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB | |
| SCHEMBL3802455 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB | |
| SCHEMBL3796473 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB | |
| SCHEMBL3802448 | 0.73 | AURKA (0.78) | PRKDCAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129605-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20230181579-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | NATIONAL INSTITUTES OF HEALTH | 2023-06-15 | — | — | US | claimed |
| US-12564589-B2 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12552793-B2 | Purine derivative and medical use thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-12514861-B2 | Targeting DNA-PKCS and B7-H1 to treat cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250288582-A1 | METHODS FOR TREATING CANCER, REDUCING SIDE EFFECTS OF CANCER TREATMENT, AND PREVENTING THE RECURRENCE OF CANCER | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-09-18 | — | — | US | disclosed |
| CN-119731177-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4514803-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250064821-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-26 | — | — | US | disclosed |
| US-20220402920-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-11504376-B2 | Targeting DNA-PKCS and B7-H1 to treat cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| EP-4086258-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-11-09 | — | — | EP | disclosed |
| US-20220228142-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-21 | — | — | US | disclosed |
| US-20220220472-A1 | TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-07-14 | — | — | US | disclosed |
| WO-2022133246-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3983542-A2 | METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIR | CRISPR Therapeutics AG (CH) | 2022-04-20 | — | — | EP | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552793-B2 | Purine derivative and medical use thereof | PNP, CYP2D6, ADORA1 | PRKDC 579/4885AURKA 1043/4885AURKB 1099/4885 |
| US-12564589-B2 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | BRCA1, PARP1, PARP2 | PRKDC 37/4885AURKA 229/4885AURKB 158/4885 |
| US-20220228142-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | HBB, HBG1, HBG2 | PRKDC 417/4885AURKA 4644/4885AURKB 2047/4885 |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | HBB, HBG1, HBG2 | PRKDC 417/4885AURKA 4586/4885AURKB 2043/4885 |
| US-12497614-B2 | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies | HBB, HBG1, HBG2 | PRKDC 417/4885AURKA 4644/4885AURKB 2047/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | PRKDC 2942/4885AURKA 3435/4885AURKB 3510/4885 |
| US-20220402920-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | DPYD, PNP, TYMP | PRKDC 131/4885AURKA 897/4885AURKB 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.